Elafibranor: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), NICE (England) and PBAC (Australia), among others, recommended or restricted elafibranor, while AOTMIT (Poland) and DMC (Denmark) did not recommend it.
Every record falls within a 1.6-year window, 14 Nov 2024 to 2 Jun 2026 — a compressed review cycle.
CIPM (Spain) changed its position: not recommended on 18 Dec 2024, recommended by 24 Apr 2025, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and AWMSG (Wales), each among the eight highest-volume agencies here.
The file is active: 12 of 12 records date from 2023 or later.
3 distinct indication wordings are recorded for elafibranor by the agencies that label one in English (NICE, PBAC and SMC).
1 of these 12 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
NICE (England) was first to assess elafibranor, on 14 Nov 2024; AOTMIT (Poland) did not open a file until 2 Jun 2026 — a moderate spread of 1.6 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 9 of 12 dated records fall in 2025 alone.
CIPM (Spain) is the only agency to have returned to elafibranor, recording 3 separate entries.
10 of the 18 agencies in this archive hold a record for elafibranor.
The full ledger for elafibranor reads 5 recommended, 4 not recommended, 1 no benefit and 1 other, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| TLV (Sweden) | 29 Oct 2025 | Iqirvo ingår i högkostnadsskyddet med generell subvention | general subsidy | source |
| DMC (Denmark) | 3 Sep 2025 | Behandling af primær biliær kolangitis som kombinationsbehandling med ursodeoxycholsyre eller som monoterapi, hvis patie… | Ikke anbefalet | source |
| PBAC (Australia) | 2025 | Primary Biliary Cholangitis (PBC) | Recommended | source |
| AIFA (Italy) | 19 May 2025 | Iqirvo è indicato per il trattamento della colangite biliare primitiva (primary biliary cholangitis, PBC) in associazion… | innovative status not granted · reimbursed class H | source |
| CIPM (Spain) | 24 Apr 2025 | Indicación terapéutica autorizada: Iqirvo está indicado para el tratamiento de la colangitis biliar primaria (CBP) en co… | financed by the SNS · art. 92 a, c | source |
7 further decisions for elafibranor, across 6 agencies, are not shown here. They include the most recent record on file, 2 Jun 2026 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 7 further source documents.
Related molecules
- obeticholic acid — divergent outcome (recommended vs not recommended) on a shared indication
- odevixibat — same ATC class A05A — Bile and liver therapy
- maralixibat — same ATC class A05A — Bile and liver therapy
- ursodeoxycholic acid — same ATC class A05A — Bile and liver therapy
- vutrisiran — also decided by AOTMIT in 2026Q2
- cerliponase alfa — also decided by AOTMIT in 2026Q2
Coverage: 12 decisions for elafibranor from 10 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class A05A — Bile and liver therapy. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.